Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:ATYRNASDAQ:OCXNASDAQ:PHATNASDAQ:TRDA On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeATYRAtyr PHARMA$5.38+0.6%$3.49$1.42▼$5.75$478.84M0.881.01 million shs2.58 million shsOCXOncoCyte$2.97$2.99$1.92▼$4.75$84.94M0.9758,121 shs49,466 shsPHATPhathom Pharmaceuticals$8.92+90.2%$4.14$2.21▼$19.71$622.74M0.151.40 million shs53.21 million shsTRDAEntrada Therapeutics$8.32+2.5%$8.23$7.10▼$21.79$315.77M-0.06133,031 shs92,685 shs7 AI Stocks to Invest in Today: Capitalizing on AI and Tech Trends in 2025Discover the top 7 AI stocks to invest in right now. This exclusive report highlights the companies leading the AI revolution and shaping the future of technology in 2025.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceATYRAtyr PHARMA+0.56%+21.44%+70.25%+58.24%+537,999,900.00%OCXOncoCyte0.00%-8.05%+5.02%-23.85%+10.41%PHATPhathom Pharmaceuticals+90.19%+110.38%+271.67%+76.28%-13.48%TRDAEntrada Therapeutics+2.46%+8.62%+1.96%-22.75%-49.21%Compare MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationATYRAtyr PHARMA2.7513 of 5 stars3.61.00.00.03.13.30.6OCXOncoCyte1.9639 of 5 stars3.44.00.00.00.60.80.6PHATPhathom Pharmaceuticals3.1097 of 5 stars3.51.00.00.03.15.00.6TRDAEntrada Therapeutics2.7885 of 5 stars3.62.00.00.02.61.71.3Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceATYRAtyr PHARMA 3.14Buy$18.60245.72% UpsideOCXOncoCyte 2.75Moderate Buy$6.06104.12% UpsidePHATPhathom Pharmaceuticals 3.00Buy$17.6097.31% UpsideTRDAEntrada Therapeutics 3.25Buy$25.67208.49% UpsideCurrent Analyst Ratings BreakdownLatest OCX, PHAT, ATYR, and TRDA Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails6/6/2025PHATPhathom PharmaceuticalsNeedham & Company LLCSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$28.006/4/2025ATYRAtyr PHARMAHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$35.005/21/2025OCXOncoCyteUBS GroupSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$8.005/21/2025OCXOncoCyteLake Street CapitalSubscribe to MarketBeat All Access for the recommendation accuracy ratingBoost Price TargetBuy ➝ Buy$5.00 ➝ $8.005/20/2025TRDAEntrada TherapeuticsHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$20.00 ➝ $20.005/19/2025ATYRAtyr PHARMAHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$35.00 ➝ $35.005/13/2025OCXOncoCyteNeedham & Company LLCSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$4.25 ➝ $4.255/2/2025PHATPhathom PharmaceuticalsThe Goldman Sachs GroupSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetNeutral ➝ Neutral$10.00 ➝ $5.005/2/2025PHATPhathom PharmaceuticalsGuggenheimSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetBuy ➝ Buy$18.00 ➝ $12.005/2/2025PHATPhathom PharmaceuticalsHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetBuy ➝ Buy$28.00 ➝ $20.004/21/2025PHATPhathom PharmaceuticalsNeedham & Company LLCSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$28.00 ➝ $28.00(Data available from 6/7/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookATYRAtyr PHARMA$235K2,037.62N/AN/A$1.54 per share3.49OCXOncoCyte$3.84M22.10N/AN/A$2.48 per share1.20PHATPhathom Pharmaceuticals$81.86M7.61N/AN/A($1.27) per share-7.02TRDAEntrada Therapeutics$172.22M1.83N/AN/A$7.26 per share1.15Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateATYRAtyr PHARMA-$50.39M-$0.81N/AN/AN/AN/A-79.44%-59.16%8/12/2025 (Estimated)OCXOncoCyte-$27.78M-$3.53N/AN/AN/A-6,122.29%-269.32%-59.71%8/6/2025 (Estimated)PHATPhathom Pharmaceuticals-$201.59M-$5.24N/AN/AN/A-1,292.14%N/A-79.57%8/14/2025 (Estimated)TRDAEntrada Therapeutics-$6.68M$0.815.23N/AN/A25.53%16.11%10.39%8/12/2025 (Estimated)Latest OCX, PHAT, ATYR, and TRDA EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails5/12/2025Q1 2025OCXOncoCyte-$0.24-$0.26-$0.02-$0.26$0.13 million$2.14 million5/8/2025Q1 2025TRDAEntrada Therapeutics-$0.78-$0.42+$0.36-$0.42$10.98 million$8.75 million5/7/2025Q1 2025ATYRAtyr PHARMA-$0.19-$0.17+$0.02-$0.17N/AN/A3/24/2025Q4 2024OCXOncoCyte-$0.40$0.48+$0.88-$1.93$0.16 million$1.49 million3/13/2025Q4 2024ATYRAtyr PHARMA-$0.23-$0.18+$0.05-$0.18$0.02 millionN/ACompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthATYRAtyr PHARMAN/AN/AN/AN/AN/AOCXOncoCyteN/AN/AN/AN/AN/APHATPhathom PharmaceuticalsN/AN/AN/AN/AN/ATRDAEntrada TherapeuticsN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioATYRAtyr PHARMA0.025.415.41OCXOncoCyteN/A0.530.50PHATPhathom PharmaceuticalsN/A5.735.68TRDAEntrada TherapeuticsN/A6.596.59Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipATYRAtyr PHARMA61.72%OCXOncoCyte55.35%PHATPhathom Pharmaceuticals99.01%TRDAEntrada Therapeutics86.39%Insider OwnershipCompanyInsider OwnershipATYRAtyr PHARMA3.70%OCXOncoCyte2.05%PHATPhathom Pharmaceuticals23.00%TRDAEntrada Therapeutics8.11%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableATYRAtyr PHARMA5389.00 million80.84 millionOptionableOCXOncoCyte12028.60 million17.18 millionNo DataPHATPhathom Pharmaceuticals11069.81 million51.90 millionOptionableTRDAEntrada Therapeutics11037.95 million34.58 millionOptionableOCX, PHAT, ATYR, and TRDA HeadlinesRecent News About These CompaniesEntrada Therapeutics, Inc. (NASDAQ:TRDA) Stock Position Trimmed by Nuveen Asset Management LLCJune 4 at 3:36 AM | marketbeat.comEntrada Therapeutics Appoints Maha Radhakrishnan, M.D., to its Board of DirectorsJune 3, 2025 | globenewswire.comEntrada Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)June 2, 2025 | globenewswire.comEntrada Therapeutics Receives Authorization in the European Union to Initiate ELEVATE-45-201, a Phase 1/2 Multiple Ascending Dose Clinical Study of ENTR-601-45 in Patients ...May 29, 2025 | morningstar.comEntrada Therapeutics to start DMD trial in Q3 2025May 29, 2025 | investing.comEntrada Therapeutics Receives EU Authorization to Proceed with ELEVATE-45-201 Clinical Study for Duchenne Muscular Dystrophy, Set to Begin in Q3 2025May 29, 2025 | nasdaq.comEntrada Therapeutics Receives Authorization in the European Union to Initiate ELEVATE-45-201, a Phase 1/2 Multiple Ascending Dose Clinical Study of ENTR-601-45 in Patients Living with Duchenne Muscular Dystrophy Amenable to Exon 45 SkippingMay 28, 2025 | globenewswire.comQ2 EPS Estimate for Entrada Therapeutics Raised by AnalystMay 24, 2025 | marketbeat.comWhat is HC Wainwright's Estimate for TRDA Q2 Earnings?May 23, 2025 | marketbeat.comNorthern Trust Corp Has $5.50 Million Holdings in Entrada Therapeutics, Inc. (NASDAQ:TRDA)May 23, 2025 | marketbeat.comEntrada Therapeutics (NASDAQ:TRDA) Given "Buy" Rating at HC WainwrightMay 22, 2025 | marketbeat.comJanus Henderson Group PLC Acquires 368,908 Shares of Entrada Therapeutics, Inc. (NASDAQ:TRDA)May 17, 2025 | marketbeat.comMPM Asset Management LLC Decreases Stock Holdings in Entrada Therapeutics, Inc. (NASDAQ:TRDA)May 16, 2025 | marketbeat.comQ2 EPS Forecast for Entrada Therapeutics Reduced by AnalystMay 16, 2025 | marketbeat.comEntrada Therapeutics, Inc. (NASDAQ:TRDA) Shares Purchased by Dimensional Fund Advisors LPMay 16, 2025 | marketbeat.comEntrada Therapeutics (NASDAQ:TRDA) Issues Earnings ResultsMay 12, 2025 | marketbeat.comAnalysts Are Upgrading Entrada Therapeutics, Inc. (NASDAQ:TRDA) After Its Latest ResultsMay 11, 2025 | finance.yahoo.comEntrada Therapeutics, Inc. (TRDA) Reports Q1 Loss, Tops Revenue EstimatesMay 8, 2025 | zacks.comEntrada Therapeutics Reports First Quarter 2025 Financial ResultsMay 8, 2025 | globenewswire.comEntrada Trims Workforce by 20 Percent to Focus on Advancing DMD, Other CandidatesMay 2, 2025 | precisionmedicineonline.comEntrada Cuts 20% of Workforce, Targeting Research EmployeesApril 30, 2025 | biospace.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeOCX, PHAT, ATYR, and TRDA Company DescriptionsAtyr PHARMA NASDAQ:ATYR$5.38 +0.03 (+0.56%) Closing price 06/6/2025 04:00 PM EasternExtended Trading$5.43 +0.05 (+0.91%) As of 06/6/2025 07:58 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.aTyr Pharma, Inc. engages in the discovery and development of medicines based on novel biological pathways. Its product pipeline includes ATYR1923, ATYR2810, NRP2 mAbs, and AARS-1, DARS-1. The company was founded by Paul Schimmel, Xiang-Lei Yang and Bruce Beutler on September 8, 2005 and is headquartered in San Diego, CA.OncoCyte NASDAQ:OCX$2.97 0.00 (0.00%) Closing price 06/6/2025 04:00 PM EasternExtended Trading$2.95 -0.02 (-0.67%) As of 06/6/2025 06:16 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.OncoCyte Corporation, a precision diagnostics company, focuses on development and commercialization of proprietary tests in the United States and internationally. The company is developing DetermaIO, a gene expression test that assesses the tumor microenvironment to predict response to immunotherapies; DetermaCNI, a blood-based monitoring tool for monitoring therapeutic efficacy in cancer patients; and VitaGraft, a blood-based solid organ transplantation monitoring test. It also provides testing services for biomarker discovery, assay design and development, clinical trial support, and various biomarker tests. The company has a collaboration agreement with Bio-Rad Laboratories, Inc. (Bio-Rad) to collaborate in the development and the commercialization of research use only and in vitro diagnostics kitted transplant products using Bio-Rad's ddPCR instruments and reagents. OncoCyte Corporation was incorporated in 2009 and is based in Irvine, California.Phathom Pharmaceuticals NASDAQ:PHAT$8.92 +4.23 (+90.19%) Closing price 06/6/2025 04:00 PM EasternExtended Trading$8.94 +0.03 (+0.28%) As of 06/6/2025 08:00 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Phathom Pharmaceuticals, Inc., biopharmaceutical company, focuses on developing and commercializing treatments for gastrointestinal diseases. The company has the rights in the United States, Europe, and Canada for an investigational potassium-competitive acid blocker (P-CAB) that blocks acid secretion in the stomach. It is also developing vonoprazan for the treatment of erosive gastroesophageal reflux disease; and in combination with antibiotics for the treatment of Helicobacter pylori infection. The company was incorporated in 2018 and is headquartered in Florham Park, New Jersey.Entrada Therapeutics NASDAQ:TRDA$8.32 +0.20 (+2.46%) Closing price 06/6/2025 04:00 PM EasternExtended Trading$8.33 +0.01 (+0.12%) As of 06/6/2025 04:04 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Entrada Therapeutics, Inc., a clinical-stage biotechnology company, develops endosomal escape vehicle (EEV) therapeutics for the treatment of multiple neuromuscular diseases. Its EEV platform develops a portfolio of oligonucleotide, antibody, and enzyme-based programs. Its therapeutic candidates, which include ENTR-601-44, which is in Phase I clinical trial for the treatment of Duchenne muscular dystrophy; and ENTR-701, which is in Phase 1/2 clinical trial for the treatment of myotonic dystrophy type 1. The company also offers ENTR-601-45 and ENTR-601-50, which are in preclinical trail for the treatment of Duchenne muscular dystrophy; and ENTR-501, an intracellular thymidine phosphorylase enzyme replacement therapy, which is in preclinical trail for the treatment of mitochondrial neurogastrointestinal encephalomyopathy. Entrada Therapeutics, Inc. has a strategic collaboration and license agreement with Vertex Pharmaceuticals Incorporated to research, develop, manufacture, and commercialize ENTR-701. The company was formerly known as CycloPorters, Inc. and changed its name to Entrada Therapeutics, Inc. in October 2017. Entrada Therapeutics, Inc. was incorporated in 2016 and is headquartered in Boston, Massachusetts. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30EcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas This Banking Giant Just Got a $90 Price Target Upgrade Broadcom Slides on Solid Earnings, AI Outlook Still Strong The Market’s Silent Warning: What Bonds and Gold Reveal MongoDB Affirms Outlook and Accelerates Stock Price Reversal Are NVIDIA's Ethernet Wins Signs of Hope or Horror for Arista? AT&T: Is This Telecom Giant a Buy or a Bye for Your Portfolio? Why Visa's Innovation Engine Keeps It a Top Portfolio Pick Is Meta Plotting a Stablecoin Comeback Years After Libra's Flop? Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
